Actively Recruiting

Age: 18Years +
All Genders
NCT06527872

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Led by GlaxoSmithKline · Updated on 2026-03-27

300

Participants Needed

5

Research Sites

233 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.

CONDITIONS

Official Title

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provide signed informed consent at enrollment per protocol
  • Male or female aged 18 years or older at initiation of belimumab
  • Received belimumab (subcutaneous or intravenous) for active LN as per local label combined with standard immunosuppressive therapy at belimumab initiation
  • Initiated belimumab 6 to 24 months prior to study enrollment
  • Accessible medical records from belimumab initiation, including 12 months prior and confirmatory biopsy before belimumab initiation
  • Biopsy-confirmed diagnosis of LN prior to belimumab initiation
  • LN Class III with or without Class V, Class IV with or without Class V, or Class V
Not Eligible

You will not qualify if you...

  • Receiving renal replacement therapy (dialysis, kidney transplant, or end-stage kidney disease) at belimumab initiation
  • Receiving another SLE targeted monoclonal antibody or one expected to compromise immune responses at belimumab initiation
  • Participating in a clinical trial during the observation period (except other non-interventional studies allowed)
  • Pregnant at belimumab initiation
  • Had a kidney transplant at belimumab initiation
  • Planning to become pregnant or pregnant at study enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

GSK Investigational Site

Baltimore, Maryland, United States, 21287

Actively Recruiting

2

GSK Investigational Site

Charlotte, North Carolina, United States, 28207

Actively Recruiting

3

GSK Investigational Site

Columbus, Ohio, United States, 43201

Actively Recruiting

4

GSK Investigational Site

Hixson, Tennessee, United States, 37343-7908

Actively Recruiting

5

GSK Investigational Site

Fukuoka, Japan, 807-8556

Actively Recruiting

Loading map...

Research Team

U

US GSK Clinical Trials Call Center

CONTACT

E

EU GSK Clinical Trials Call Center

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN | DecenTrialz